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At present there is no universally accepted defini-
tion of intrauterine growth retardation (IUGR). In
this report IUGR infants are defined as those with
a birth weight below — 2 SD of the normal mean
for the gestational age [7]. These infants have a
high perinatal mortality [21] and morbidity [11].
For detection of IUGR both the "gravidogram"
[29] and ultrasound examination [23] have been
found to be effective methods.
For monitoring of already diagnosed or suspected
cases of IUGR the concentrations of several
products of the fetus and/or the placenta have
been measured in maternal blood or urine. Among
the most frequently evaluated for this purpose
have been estriol [17] and human placental lacto-
gen(HPL)[16].
During the last 10 years many additional bio-
chemical markers have been identified. One of
them is pregnancy-specific jSj-glycoprotein (SPj)
[2], which is a placental product [12]. During
late pregnancy the serum concentration of SP1
correlates with infant birth weight and placental
weight both in uncomplicated and in complicated
pregnancies [24, 26, 28].
Previous reports have indicated that SPt seems
promising as a predictor of IUGR [8,25, 28]. The
aim of the present study was to examine the
possibility of detecting and monitoring IUGR
from SPj concentrations in maternal serum,
measured by nephelometry, during pregnancy
weeks 29 to 40. The SPi values obtained were
compared with a reference range of serum SPj
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levels in uncomplicated single pregnancies from a
cross-sectional study [24] and with serial values
from individual women with uncomplicated single
pregnancies.
1 Material and methods
Thirty-seven women in pregnancy weeks 29 to 40,
all of whom subsequently gave birth to single
IUGR infants, volunteered for this study. A total
of 67 blood samples were obtained for SP1 ana-
lyses. The women were 19 to 42 years old (mean
27 years). Twenty-three women were primiparous
and 14 were multiparous. Detailed clinical data on
these women are given in Tab. I. Preeclampsia was
diagnosed and classified according to the criteria
of the U. S. Comittee on Maternal Welfare issued
in 1952 [18]. The WHITE classification was used
for diabetes mellitus [19].
0300-5577/83/0011-0019$02.00
© by Walter de Gruyter & Co. · Berlin · New York
20 Tamsen et al., SPi in IUGR
Tab. I. Clinical grouping of 37 women with pregnancies
complicated by intrauterine growth retardation (infant
birth weight below - 2 SD of the normal mean for
the gestational age) [7].
Group APGAR score at 1 minute
<6 >7
Total
No maternal
complication 1
Pre-eclampsia
levis 3**
Pre-eclampsia
gravis 5
Diabetes
mellitus
group D 1**
group F
Miscellaneous1) 1
Total 11
11
6*
2
1
6**
26
12
9
7
1
1
7
37
1) essential hypertension, pre-partum hemorrhage, pre-
mature rupture of the membranes, ulcerative colitis,
cervical insufficiency, congenital malformation
+ two stillborns
* one pre-partum hemorrhage
** one lethal congenital malformation
Cesarean sections were performed on 19 women
from pregnancy weeks 29 to 41 because of mater-
nal and/or fetal complications. In all, 10 infants
were born before the 35th week of pregnancy.
Induced or spontaneous vaginal labor occurred in
pregnancy weeks 36 to 42 except in three cases,
where stillborn infants were delivered in weeks 30
to 36 of pregnancy, one with a lethal congenital
malformation. Another infant died later from
lethal congenital malformation.
From 21 women with uncomplicated single preg-
nancies giving birth to healthy infants of normal
birth weight [7] in pregnancy weeks 38 to 42, 210
blood samples were collected weekly or biweekly.
Serum or plasma was stored at — 20°C until
assayed.
Nephelometry was performed as described else-
where [24]. The interassay variation was 5 % and
the detection limit 0.5 mg/1. No differences were
found between plasma and serum concentrations
of SPi [24]. Whether the analyses were performed
on plasma or serum, the term "serum concentra-
tion" will be used in the following.
The reference range of serum SPj concentrations
for uncomplicated single pregnancies used for
comparison with the SP^ values obtained is the
same as previously described [24].
2 Results
The SPj values in 67 blood samples from 37
women with single pregnancies complicated by
IUGR are illustrated in Fig. 1. Most of the values
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Fig. 1. Pregnancy-specific ^-glycoprotein (SPj) levels
measured by nephelometry in serum from 37 women
(67 samples) with single pregnancies complicated by
intrauterine growth retardation (infant birth weight
below — 2 SD of the normal mean for the gestational
age) [7J.
The shaded area represents a 95 % reference range for SPj
levels in uncomplicated single pregnancies obtained from
a cross-sectional study of 323 women [24], and the solid
line is the geometric mean.
The following symbols are used: APGAR score at 1
minute > 7 (·), idem < 6 (o), an infant with acrania and
other malformations (Δ), an infant with ZELLWEGER's
syndrome (A), an infant stillborn in pregnancy week 30
(+) and one stillborn in pregnancy week 35 (++).
The woman with an extremely low SPj value [1] had a
normal value of human placental lactogen.
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were below the geometric mean of the reference
group and serial samples showed a tendency to a
decrease in SPj levels, which was more marked
when the APGAR score at l min was low.
A serum SPj value of 80mg/l (approximately
corresponding to the geometric mean — 1 SD)
was chosen as the most appropriate discriminatory
level between uncomplicated pregnancies and
pregnancies complicated by IUGR in gestational
weeks 32 to 34. The distributions of the initial
SPj values among women with IUGR infants
and those with uncomplicated pregnancies in
relation to the 80 mg/1 level were compared and
the results are given in Table II. Of 15 women with
IUGR infants, 10 (67%) had a serum S?l value
below 80 mg/1, while the corresponding figure for
uncomplicated pregnancies was 10 out of 76
women (13%).
The SPi values in serial samples from 21 women
with uncomplicated pregnancies are presented in
Fig. 2. From pregnancy weeks 30 to 36 there
was a steady increase in the SPj concentration
and after week 36 there was a tendency to a
plateau. Using the function for linear regression
log y = ax + b, where y = SPj value and χ = preg-
nancy week, two average linear developments
were determined (Fig. 3). The mean increase in
the SPj concentration from pregnancy weeks
o//o
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Fig. 2. Pregnancy-specific j-glycoprotein (SPj) levels
measured by nephelometry in serum from 21 women with
uncomplicated single pregnancies (total 210 samples). The
infants were born in pregnancy weeks 38 to 42 and were
healthy and of normal weight (mean ± 2 SD for the
gestational age) [7].
The shaded area represents a 95 % reference range for SPj
levels in uncomplicated single pregnancies obtained from
a cross-sectional study of 317 women [24].
*) This woman had normal serum values of alpha-feto-
protein, estriol and human placental lactogen.
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Fig. 3. The mean increase ± 1 SD (solid line and shaded
area) in the serum concentration of pregnancy-specific
01-glycoprotein (SPj), measured by nephelometry, in
serial samples from 21 women with uncomplicated single
pregnancies in pregnancy weeks 30 to 36, in percent of
the initial value. The mean increase of the 8Ρχ concen-
tration is continued for pregnancy weeks 36 to 40.
The developments of the SPj levels in serum from six
women with pregnancies complicated by intrauterine
growth retardation (infant birth weight below - 2 SD
of the normal mean for the gestational age) [7] are also
shown. Serial samples from each woman are connected
with a solid line; open circles represent an APGAR score
or < 6 at l min and closed circles an APGAR score of
> 7 at l min.
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30 to 36 was 49%. During weeks 36 to 40 the
mean increase was 13 %.
The S?i values in serum from six women with
IUGR infants from whom at least three serial
samples were drawn over a period of at least two
weeks showed a decreasing tendency (Fig. 3.)·
The decline was most marked in the woman
whose infant had a low APGAR score at l min
after birth.
3 Discussion
As the etiology of IUGR is multifactorial [15], no
single abnormal clinical or biochemical finding is
sufficient in itself for diagnosis and intervention.
Reliable diagnosis of this condition and/or moni-
toring of already diagnosed IUGR must depend
upon a combination of clinical and laboratory
approaches [9] as well as on an accurate estima-
tion of gestational age. If there is any doubt about
the length of a pregnancy* an early ultrasound
examination will give correct dating [3]. With
reliable dating, the simple "gravidogram" can
be used as a routine examination and 75% of
infants of low birth weight for their gestational age
can be detected [29]. An ultrasound examination
measuring the biparietal diameter and the body
circumference [23] can confirm suspected growth
retardation.
However, even if the fetus and the placenta
together form one entity, the causes of IUGR can
be mainly fetal (e.g. congenital malformation) or
purely placental [15]. It might therefore be of
value to combine at least two biochemical markers
that mainly depend on the status of either the
fetus or the placenta.
Of the placental proteins, HPL is the hitherto
most frequently evaluated in different complica-
tions during late pregnancy [14]. Like SPj, it
has a low day-to-day variation, but the concentra-
tion of HPL in maternal serum is about 20—30
times lower than that of SPj [27] and for ana-
lyses of HPL a sensitive method such as a radio-
immunoassay or an enzyme immunoassay has to
be used. SPl9 however, is easily measured by
simple immunoprecipitation methods or nephelo-
metry [24].
In earlier studies in which SPi was compared with
HPL, the predictive value of SPj for IUGR was
found to be equally good as [22] or even better
than that of HPL [28].
In the present investigation it was found that a
serum 8Ρχ level below 80 mg/1 in a single blood
sample drawn in pregnancy weeks 32 to 34 had a
predictive value of 50% for IUGR and that a level
above or at 80 mg/1 had a value of 93 % for pre-
dicting a normal infant birth weight (Tab. II). In
this study IUGR infants were defined as those
with a birth weight below — 2 SD of the normal
mean for the gestational age [7]. Even if other
reports define IUGR as a birth weight below the
10th percentile of normal infant birth weight for
the gestational age, it would seem of interest to
compare our results with those of other studies.
CHAPMAN etal. [5] used a serum SP1 value of
100 mg/1 as a cut-off level in pregnancy weeks 31
to 34 and found a predictive value of 24 % for
Tab. II. Sensitivity and predictive value of a single value
of pregnancy^specific ^-glycoprotein (SP^ in serum,
with 80 mg/1 as the discriminatory level between uncom-
plicated pregnancies and pregnancies complicated with
IUGR (infant birth weight below - 2 SD of the normal
mean for the gestational age [7]). The S?! levels in the
first blood samples drawn in pregnancy weeks 32 to 34
from 15 women were compared with the 8Ρχ levels from
a cross-sectional study of uncomplicated single preg-
nancies [24] for the same period,
η = number of women
TP = true positive and FP = false positive, i.e. SPj level
= > 80 mg/1.
TN = true negative and FN = false negative, i.e. 8Ρχ level
< 80 mg/1.
IUGR
(n)
8Ρχ level
< 80 mg/1 10
SPj level
> 80 mg/1 5
Total 15
TN
aensmvny TN + FP
TNPredictive value τ^χτ τ?χτ ~" 50%
Uncomplicated
pregnancy (n)
10
66
76
TP
' TP + FN
TP
TP + FP
86.8%
92.9%
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IUGR. GORDON etal. [8] reported that during
pregnancy weeks 31 to 40 more than 70% of
women with IUGR infants had SPj concentrations
below the 10th percentile of the reference range.
TOWLER et al. [28] found the predictive value of
8Ρχ levels below a 95 % reference range for detec-
tion of IUGR to be 60% during the last trimester.
Thus, despite differences in the definition of
IUGR and in the selection of reference ranges, the
predictive values of the serum SPi level for IUGR
are in the same range.
During uncomplicated single pregnancies, there
was an average increase of 49% in the SPj con-
centration from pregnancy weeks 30 to 36 as
assessed from serial samples from individual
women (Fig. 3). It was also found that each
individual woman maintained a certain concentra-
tion level throughout late pregnancy, i.e. they all
showed the same relative increase but at individual
levels. In serial samples from women with IUGR
infants there was no such increase and even a
decrease occurred (Fig. 3), a finding indicating
that serial measurements of SPj can be used for
monitoring cases of suspected IUGR. An absence
of an increase in the SPj concentration, or the
occurrence of a decrease, will strengthen the
suspicion of IUGR. Besides, very low values or an
early decrease seem to correlate with a low APGAR
score.
One woman with an IUGR infant had an extrem-
ely low serum SPX value (Fig. 1). A similar case has
only been reported once [10], suggesting a rare
and specific defect in the SPj synthesis, as both
these women had normal HPL values. It is of
interest to note that a similar rare deficiency has
been reported for HPL in cases with a normal
pregnancy and delivery. In these cases the SPj
values were normal [1,6,20]. An immunosuppres-
sive effect of SPj has been found in studies in vitro
[4, 13], which could indicate that SP1 has a
function as an immunological protector of the
pregnancy against the mother, but the findings of
very low 8Ρχ values in rare cases might cast some
doubt on this suggestion.
In pregnancies complicated by congenital malfor-
mations combined with IUGR (Fig. 1) no special
pattern of SPi values was found as compared with
the reference group of uncomplicated pregnancies.
This finding is interesting. A normal serum SPj
value in a woman with an IUGR infant could point
towards a fetal cause of the growth retardation,
e.g. congenital malformation.
It is concluded that SPl measurements are valuable
adjuncts to the "gravidogram" and ultrasonar
examination for the detection and monitoring of
IUGR. As the day-to-day variation of SPX is low,
as is the methodological variation of nephelo-
metry, a determination of SP1 in a single sample is
in most cases sufficient to detect pregnancies at
risk of IUGR in the beginning of the last trimester.
Serial determinations will increase the predictive
value even further.
Summary
Serum concentrations of pregnancy-specific /3j-glyco-
protein (SPi) were measured by nephelometry in 37
women with single pregnancies complicated by intra-
uterine growth retardation (IUGR). Sixty-seven blood
samples were examined for their contents of SPj in
pregnancy weeks 29 to 40. The SPj values were compared
with those obtained in a cross-sectional study of 323
women and a serial study of 21 women (210 samples)
with uncomplicated single pregnancies.
It was found that a serum SPj value below 80 mg/1 in a
single blood sample drawn in pregnancy weeks 32 to 34
had a predictive value of 50% for IUGR and a value
above or at 80 mg/1 had a value of 93 % for predicting a
normal infant birth weight.
Serial samples from individual women with uncom-
plicated single pregnancies showed an average increase in
the SPj concentration of 49 % from pregnancy weeks 30
to 36. In serial samples from six women with IUGR
infants there was no such increase, or a decrease occurred.
It is concluded that SPj measurements in maternal serum
are valuable for the detection and monitoring of preg-
nancies complicated by IUGR.
Keywords: Fetal growth retardation, human pregnancy, nephelometry, placental function tests, pregnancy proteins,
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Zusammenfassung
Schwangerschaftsspezifisches jSj-Glukoprotein (SPi) im
mütterlichen Serum bei Schwangerschaften mit intra-
uteriner Mangelentwicklung
Bei 37 Frauen mit Einzelschwangerschaften, kompliziert
durch intrauterine Mangelentwicklung, wurden nephelo-
metrisch die Serumkonzentrationen des schwanger-
schaftsspezifischen 0rGlukoproteins (8 ) bestimmt. In
67 Blutproben wurde der SPx-Gehalt in der 29- bis 40.
Schwangerschaftswoche bestimmt. Als Vergleich zu
diesen SPj-Werten dienten die Ergebnisse einer Reihen-
untersuchung an 323 Frauen und die Serienuntersuchun-
gen an 21 Frauen (mit 210 Einzelproben), bei denen Ein-
zelschwangerschaften komplikationslos verlaufen waren.
Wir fanden, daß eine SPj-Konzentration < 80 mg/1 -
bestimmt in der 32. bis 34. Schwangerschaftswoche —
einen prognostischen Wert von 50%, eine SPx-Konzen-
tration > 80 mg/1 einen proighostischen Wert von 93 %
für ein normales Geburtsgewicht des Kindes hat.
Serienuntersuchungen einzelner Frauen mit komplika-
tionslosen Einzelschwangerschaften zeigten zwischen der
30. bis 36. Schwangerschaftswoche eine durchschnittliche
Zunahme der SPi-Konzentration ufn 49%. Serienunter-
suchungen an 6 Frauen mit intrauterin mangelentwickel-
ten Kindern ließen diese Zunahme nicht erkennen, hier
trat im Gegenteil eine Abnahme ein. Wir schließen aus
unseren Ergebnissen, daß ISP j -Bestimmungen in regel-
mäßigen Abständen ein wertvoller Parameter für die
Erkennung und Verlaufskontrolle von Schwangerschaften
mit intrauterin mangelentwickeltem Kind sind.
Schlüsselwörter: Fetale Wachstumsretardierung, Nephelometrie, Plazentafunktionstest, schwangerschaftsspezifische
Proteine, SP .
Resume
Glycoprotein ßi (SPj) specifique de la grossesse dans le
serum de femmes dont la grossesse est compliquee d'ün
retard de croissance intra-uterin
Des concentrations de glycoproteine (SPj), specifique de
la grossesse, ont ete mesurees par nephelometrie chez 37
femmes presentant des grossesses uniques compliquees de
retard de croissance intra-uterin (RCIU), 67 prelevements
de sang ont ete analyses pour determiner le taux de SPj
de la 29eme ä la 40eme semaine de grossesse. Les taux
de SPj releves ont ete compares "ä ceux obtenus par
Fetude d'un groupe de 323 femmes ~et l'etude serielle de
21 femmes (210 prelevements) presentant des grossesses
uniques normales.
II a ete mis en evidence qu'un taux de serum SPj inferieur
a 80 mg/1 dans un seul prelevement sanguin effectue de la
32eme ä la 34eme semaine de grossesse avait une valeur
diagnostique de 50 % pöür un RCIU et qu'un taux egal ou
superieur ä 80 mg/1 permettait de diagnostiquer ä 93 % un
poids de naissance normal.
Des prelevements periodiques effectues individuellement
sur des femmes presentant une grossesse simple sans
complications ont montre une augmentation moyenne de
la concentration de SPj de 49% de la 30eme a la 36eme
semaine de grossesse. Lors d'une serie de prelevements
effectues sur des femmes presentant un RCIU, U n'a ete
constate ni augmentation, ni dimination.
En conclusion, les mesures de SPj effectuees sur le serum
maternel jouent un role important dans la detection et la
surveillance des grossesses compliquees de RCIU.
Mots-cles: Grossesse, nephelometrie, proteines de la grossesse, retard de croissance foetal, SPj, tests de function
placentaire.
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